Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

20.39 -4.48 (-18.01%)
Streaming Delayed Price Updated: 3:10 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tango Therapeutics, Inc. - Common Stock

News headline image
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Announces Discontinuation of TNG348 Program
From Tango Therapeutics
Via Business Wire
News headline image
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs
From The Briscoe Law Firm, PLLC
Via Business Wire
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
From Tango Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.